Introduction {#Sec1}
============

People with diabetes have a higher risk of developing incident heart failure (HF) than those without diabetes \[[@CR1]--[@CR3]\] and among patients with HF, those with diabetes have worse outcomes than patients without diabetes \[[@CR4]--[@CR6]\]. The latter observation is of considerable import because the prevalence of co-existing diabetes is high among patients with HF, affecting between 25 and 50% of individuals depending on which study is examined.

Recently, both undiagnosed diabetes and prediabetic dysglycemia were also found to be common in patients with HF with reduced ejection fraction (HFrEF) and each was associated with worse outcomes, compared with normoglycemia, although the risk was not as high as in patients with diagnosed diabetes \[[@CR7]\]. The aim of our study was to determine the prevalence and prognostic significance of undiagnosed diabetes and prediabetic dysglycemia in the other major HF phenotype, HF with preserved ejection fraction (HFpEF), and compare the prevalence and outcomes with those in contemporaneously recruited patients with HFrEF. To do this, we used data from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme, which included patients with HFrEF and HFpEF \[[@CR6], [@CR8]\].

Methods {#Sec2}
=======

The CHARM-Programme consisted of one HFpEF trial and two HFrEF trials. CHARM-Preserved enrolled 3023 patients 18 years or older, in York Heart Association (NYHA) functional class II--IV, with a prior hospitalization for a cardiac reason and a left ventricular ejection fraction (LVEF) above 40% \[[@CR8]\]. CHARM-Alternative and CHARM-Added included 2028 and 2548 patients, respectively, aged 18 years or older, in NYHA functional class II-IV, with a LVEF of 40% or less, either treated with an angiotensin converting enzyme (ACE) inhibitor (CHARM-Added) or not, because of intolerance (CHARM-Alternative) \[[@CR8]\]. As previously reported, glycated hemoglobin (hemoglobin A1c, HbA1c) was measured at baseline in the 2650 CHARM patients enrolled in Canada and the USA \[[@CR6]\]. We categorized glycemic status in individuals without a history of diabetes using the International Diabetes Expert Committee criteria: normoglycemia (HbA1c \< 6.0%), prediabetic dysglycemia (HbA1c 6.0--6.4%) and undiagnosed diabetes (HbA1c \> 6.4%) \[[@CR9]\]. Patients with a prior diagnosis of diabetes were considered to have diabetes irrespective of HbA1c level.

We used multivariable Cox proportional hazards models to evaluate the primary composite outcome of CHARM, which was death from cardiovascular (CV) causes or a hospitalization for HF, as well as all-cause mortality, according to glycemic status. Analyses were adjusted for age, sex, treatment arm, ejection fraction, NYHA class, heart rate, systolic blood pressure, body mass index (BMI), history of coronary artery bypass grafting, percutaneous coronary intervention, implantable cardioverter defibrillator, stroke and atrial fibrillation.

Results {#Sec3}
=======

HbA1c was available in 1072/3023 (35%) of the patients in CHARM-Preserved and 428 patients with a HbA1c measurement in this trial had a history of diabetes (Table [1](#Tab1){ref-type="table"}). Patients with diabetes were older, had a higher BMI, more evidence of coronary heart disease, worse NYHA class, higher heart rate, lower estimated glomerular filtration rate (eGFR) and greater use of loop diuretics compared to those with normoglycemia. Patients with previously undiagnosed diabetes and those with prediabetes had a clinical picture in between individuals with known diabetes and those with normoglycemia (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of patients with in CHARM-Preserved with HbA1c available, according to glycemic statusNo prior diagnosis of diabetesPrior diabetes*p* valueHbA1c \< 6.0HbA1c 6.0--6.4HbA1c \> 6.4Any HbA1cPatients, no (%)189 (18%)217 (20%)238 (22%)428 (40%)Age, years63 ± 1267 ± 1169 ± 1165 ± 11\< 0.001Female, *n* (%)82 (43%)94 (43%)100 (42%)187 (44%)0.98HbA1c, median (Q1--Q3)5.6 (5.5--5.7)6.1 (6.0--6.2)6.7 (6.5--7.1)7.8 (7.1--9.0)\< 0.001NYHA class, *n* (%)0.0006 II105 (56%)120 (55%)115 (48%)168 (39%) III81 (43%)94 (43%)119 (50%)246 (57%) IV3 (2%)3 (1%)4 (2%)14 (3%)Ejection fraction0.56 ± 0.100.55 ± 0.090.55 ± 0.090.54 ± 0.090.25Heart rate, bpm68 ± 1169 ± 1170 ± 1272 ± 11\< 0.001SBP, mmHg132 ± 19133 ± 17133 ± 18134 ± 170.86BMI, kg/m^2^29.4 ± 6.429.8 ± 6.329.8 ± 6.832.9 ± 7.1\< 0.001eGFR, ml/min/1.73m^2^82 ± 2274 ± 2370 ± 2569 ± 27\< 0.001Medical history, *n* (%) Ischemic etiology81 (43%)108 (50%)122 (51%)241 (56%)\< 0.001 Prior CABG39 (21%)59 (27%)67 (28%)144 (34%)\< 0.001 Prior PCI33 (17%)43 (20%)52 (22%)94 (22%)0.59 Prior stroke16 (8%)24 (11%)19 (8%)53 (12%)0.25 Prior AF51 (27%)73 (34%)87 (37%)121(28%)0.07 Loop diuretic110 (58%)144 (66%)162 (68%)319 (75%)\< 0.001 Digoxin56 (30%)68 (31%)87 (37%)158 (37%)0.21 β-blocker106 (56%)123 (57%)129 (54%)243 (57%)0.93 MRA17 (9%)22 (10%)18 (8%)52 (12%)0.27*HbA1c* hemoglobin A1c, *NYHA* New York Heart Association functional class, *SBP* systolic blood pressure, *BMI* body mass index, *eGFR* estimated glomerular filtration rate, *CABG* coronary artery bypass graft, *PCI* percutaneous coronary intervention, *AF* atrial fibrillation, *MRA* mineralocorticoid receptor antagonist

HbA1c was available in 1578/4576 (34%) of individuals in CHARM-Alternative and CHARM-Added, and 558 patients in these trials with a HbA1c measurement had a history of diabetes (Table [2](#Tab2){ref-type="table"}). Similar to what was observed in HFpEF, we found that patients with known or undiagnosed diabetes were older, had a worse NYHA class distribution and kidney function and were more likely to have evidence of coronary heart disease.Table 2Baseline characteristics of patients with in CHARM-Added/Alternative with HbA1c available, according to glycemic statusNo prior diagnosis of diabetesPrior diabetes*p* valueHbA1c \< 6.0HbA1c 6.0--6.4HbA1c \> 6.4Any HbA1cPatients, no (%)254 (16%)349 (22%)417 (26%)558 (35%)Age, years61 ± 1365 ± 1267 ± 1164 ± 10\< 0.001Female, *n* (%)67 (26%)93 (27%)108 (26%)152 (27%)0.97HbA1c, median (Q1--Q3)5.6 (5.4--5.7)6.1 (6.0--6.2)6.7 (6.5--7.1)8.1 (7.1--9.3)\< 0.001NYHA class, *n* (%)0.028 II93 (37%)104 (30%)124 (30%)139 (25%) III155 (61%)238 (68%)278 (67%)398 (71%) IV6 (2%)7 (2%)15 (4%)21 (4%)Ejection fraction0.28 ± 0.080.29 ± 0.090.27 ± 0.080.27 ± 0.08\< 0.001Heart rate, bpm71 ± 1272 ± 1272 ± 1275 ± 12\< 0.001SBP, mmHg125 ± 18124 ± 19123 ± 19126 ± 190.09BMI, kg/m^2^27.9 ± 4.927.5 ± 5.728.1 ± 5.730.3 ± 6.1\< 0.001eGFR, ml/min/1.73m^2^81 ± 2372 ± 2468 ± 2567 ± 26\< 0.001Medical history, *n* (%) Ischemic etiology134 (53%)212 (61%)268 (64%)390 (70%)\< 0.001 Prior CABG78 (31%)112 (32%)142 (34%)216 (39%)0.08 Prior PCI42 (17%)57 (16%)80 (19%)137 (25%)0.007 Prior stroke19 (7%)31 (9%)54 (13%)63 (11%)0.091 Prior AF62 (24%)92 (26%)128 (31%)149 (27%)0.29 Loop diuretic174 (69%)258 (74%)333 (80%)460 (82%)\< 0.001 Digoxin165 (65%)222 (64%)267 (64%)394 (71%)0.07 β-blocker136 (54%)163 (47%)232 (56%)330 (59%)0.003 MRA44 (17%)52 (15%)93 (22%)100 (18%)0.06*HbA1c* hemoglobin A1c, *NYHA* New York Heart Association functional class, *SBP* systolic blood pressure, *BMI* body mass index, *eGFR* estimated glomerular filtration rate, *CABG* coronary artery bypass graft, *PCI* percutaneous coronary intervention, *AF* atrial fibrillation, *MRA* mineralocorticoid receptor antagonist

Only 18% of patients with HFpEF and 16% of patients with HFrEF were normoglycemic.

Prediabetes was more common than normoglycemia in both types of HF: 20% in patients with HFpEF and 22% in those with HFrEF (*p* = 0.25).

The prevalence of undiagnosed diabetes was also high, but was less common in patients with HFpEF compared with HFrEF (22 vs. 26%, *p* = 0.01). Conversely, the prevalence of known diabetes was higher in patients with HFpEF (40 vs 35%, *p* = 0.02). As a result, the prevalence of any diabetes (diagnosed and previously undiagnosed) was 62% in each study.

HFpEF and HFrEF patients with diagnosed diabetes were at significantly higher risk of both the primary composite outcome, and all-cause mortality, compared with normoglycemic patients (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The rates of both outcomes of interest were higher in patients with undiagnosed diabetes and prediabetes, compared with normoglycemic patients, *p* \< 0.001 for trend across dysglycemia categories for both HFpEF and HFrEF.Fig. 1Adjusted risk for the primary composite outcome and all-cause mortality in CHARM-Preserved for each glycemia category Fig. 2Adjusted risk for the primary composite outcome and all-cause mortality in CHARM-Alternative/Added for each glycemia category

Discussion {#Sec4}
==========

We found that the prevalence of diagnosed diabetes was higher in patients with HFpEF (40%) in CHARM than in those with HFrEF (35%). However, the novel data in the present report relate to the prevalence of undiagnosed diabetes and prediabetic dysglycemia, each of which were more common than a normal HbA1c in both HFpEF and HFrEF. Indeed, when undiagnosed and diagnosed diabetes were combined, a remarkable 62% of patients with each type of HF had diabetes. An additional fifth or so of patients had prediabetes, leaving just approximately one in six patients with a normal HbA1c, an observation that was true for both HFrEF and HFpEF. In comparison 26% had a normal HbA1c and 49% had either diagnosed or undiagnosed diabetes in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF), and corresponding numbers were 30 and 41%, respectively, in the Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial \[[@CR10]\]. One explanation for the higher prevalence in CHARM (irrespective of HF type) is that HbA1c was only measured in North American patients where the prevalence of diabetes is high, with the latest reports estimating that in the general population almost 10% have diagnosed or undiagnosed diabetes and another 34% of the population have prediabetes \[[@CR11]\].

As was recently reported for patients with HFrEF, undiagnosed diabetes and prediabetic dysglycemia in patients with HFpEF (and HFrEF) in the present study were associated with worse outcomes than observed in patients with a normal HbA1c. Although this pattern was very similar to that reported in the PARADIGM-HF trial, no elevated risk was reported for patients with prediabetes in GISSI-HF. The difference in risk in the present study was not statistically significant, probably because of the smaller number of subjects with a HbA1c measurement in CHARM \[[@CR7]\]. Although we found relative similar prevalences of dysglycemia in patients with HFpEF and HFrEF in the current study, the patients with these two phenotypes differed in respect of many of their baseline characteristics. Patients with HFrEF were more likely to have ischemic etiology, worse NYHA class and were less likely to be female. To some extent, the finding of a similarly high rate of dysglycemia in these two quite distinct phenotypes suggests that the syndrome of HF per se plays some role in the development of prediabetes and diabetes. Notably, insulin resistance is present in patients with idiopathic dilated cardiomyopathy as well as in those with ischemic cardiomyopathy, and it is greater in patients with coronary artery disease and HF than in patients with coronary artery disease without HF and is not correlated with ejection fraction \[[@CR12]--[@CR14]\]. These findings suggest that the high prevalence of dysglycemia in HF is not explained by recognized associations, e.g. with atherosclerosis and is related to HF per se, independently of ventricular function.

Like PARADIGM-HF, our study has the limitation of a single HbA1c value without a confirmatory measurement and the additional limitation of only including patients from North America where the prevalence of diabetes is higher than in other geographic regions, which may introduce a selection bias and impair applicability of our results to other regions of the world.

However, even with these limitations, our data confirm the remarkably high prevalence of dysglycemia in HFrEF and show that a similarly high prevalence is found in HFpEF (with only 16--18% of patients having a normal HbA1c). In both types of HF, dysglycemia is associated with a higher risk of adverse clinical outcomes, even before the diagnosis of diabetes. These findings raise questions about the potential value of screening (for undiagnosed diabetes) and treatment targeted at correcting dysglycemia in patients with both HF phenotypes \[[@CR15]\].

The CHARM programme was funded by AstraZeneca.

Conflict of Interest {#FPar2}
====================

Drs. Kristensen, Jhund and Lee report no relevant conflict of interests. All other authors have received honoraria as steering committee members of CHARM from AstraZeneca.

Ethical Approval {#FPar3}
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
